Darolutamide does not interfere with OATP ‐mediated uptake of docetaxel
International Journal of Cancer · 2024
DOI: 10.1002/ijc.34922 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Stefan A J Buck und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Docetaxel, Solute Carrier Organic Anion Transporter Family Member 1B3, Prostatic Neoplasms, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The addition of darolutamide, an androgen receptor signalling inhibitor, to therapy with docetaxel has recently been approved as a strategy to treat metastatic prostate cancer. OATP1B3 is an SLC transporter that is highly expressed in prostate cancer and is responsible for the accumulation of substrates, including docetaxel, into tumours. Given that darolutamide inhibits OATP1B3 in vitro, we sought to characterise the impact of darolutamide on docetaxel pharmacokinetics. We investigated the influence of darolutamide on OATP1B3 transport using in vitro and in vivo models. We assessed the impact of darolutamide on the tumour accumulation of docetaxel in a patient‐derived xenograft (PDX) model and on an OATP1B biomarker in patients. Darolutamide inhibited OATP1B3 in vitro at concentrations higher than the reported C max . Consistent with these findings, in vivo studies revealed that darolutamide does not influence the pharmacokinetics of Oatp1b substrates, including docetaxel. Docetaxel accumulation in PDX tumours was not decreased in the presence of darolutamide. Metastatic prostate cancer patients had similar levels of OATP1B biomarkers, regardless of treatment with darolutamide. Consistent with a low potential to inhibit OATP1B3‐mediated transport in vitro, darolutamide does not significantly impede the transport of Oatp1b substrates in vivo or in patients. Our findings support combined treatment with docetaxel and darolutamide, as no OATP1B3 transporter based drug–drug interaction was identified.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
- Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
- Division of Outcomes and Translational Sciences, College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
- Department of Urology, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
ORCID-Profile: Stefan A J Buck, Eric D Eisenmann
Zitieren
APA
Buck, S. A. J., Talebi, Z., Drabison, T., Jin, Y., Gibson, A. A., Hu, P., de Bruijn, P., de Ridder, C. M. A., Stuurman, D., Hu, S., van Weerden, W. M., Koolen, S. L. W., de Wit, R., Sparreboom, A., Mathijssen, R. H. J., & Eisenmann, E. D. (2024). Darolutamide does not interfere with OATP ‐mediated uptake of docetaxel. International Journal of Cancer. https://doi.org/10.1002/ijc.34922
Vancouver
Buck SAJ, Talebi Z, Drabison T, Jin Y, Gibson AA, Hu P, et al. Darolutamide does not interfere with OATP ‐mediated uptake of docetaxel. International Journal of Cancer. 2024. doi:10.1002/ijc.34922
BibTeX
@article{Buck2024,
author = {Buck, Stefan A J and Talebi, Zahra and Drabison, Thomas and Jin, Yan and Gibson, Alice A and Hu, Peng and de Bruijn, Peter and de Ridder, Corrina M A and Stuurman, Debra and Hu, Shuiying and van Weerden, Wytske M and Koolen, Stijn L W and de Wit, Ronald and Sparreboom, Alex and Mathijssen, Ron H J and Eisenmann, Eric D},
title = {Darolutamide does not interfere with OATP ‐mediated uptake of docetaxel},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.34922}
}
EUVIMED